Patents by Inventor K. Raja Reddy

K. Raja Reddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors
    Patent number: 6919322
    Abstract: Novel FBPase inhibitors of the formula I are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: July 19, 2005
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Brett C. Bookser, Qun Dang, K. Raja Reddy
  • Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
    Publication number: 20040192651
    Abstract: Compounds of Formula I, their preparation and synthetic intermediates, and their use in the synthesis of prodrugs: 1
    Type: Application
    Filed: October 31, 2003
    Publication date: September 30, 2004
    Inventors: K. Raja Reddy, William Craigo, Zhili Sun, Serge Boyer, Bheemarao G. Ugarkar
  • Prodrugs for liver specific drug delivery
    Patent number: 6752981
    Abstract: The present invention is directed towards novel cyclic phosph(oramid)ate prodrugs of alcohol, amine-, and thiol-containing drugs, their preparation, their synthetic intermediates, and their uses. Another aspect of the invention is the use of the prodrugs to treat diseases that benefit from enhanced drug distribution to the liver and like tissues and cells that express cytochrome P450, including hepatitis, cancer, liver fibrosis, malaria, other viral and parasitic infections, and metabolic diseases where the liver responsible for the overproduction of the biochemical end product, e.g. glucose (diabetes); cholesterol, fatty acids and triglycerides (hyperlipidemia) (atherosclerosis) (obesity). In one apsect, the invention is directed towards the use of the prodrugs to enhance oral drug delivery. In another aspect, the prodrugs are used to prolong pharmacodynamic half-life of the drug. In addition, the prodrug methodology of the current invention is used to achieve sustained delivery of the parent drug.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: June 22, 2004
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Mark D. Erion, K. Raja Reddy
  • Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
    Publication number: 20040058892
    Abstract: Novel FBPase inhibitors of the formula I and X 1
    Type: Application
    Filed: August 6, 2003
    Publication date: March 25, 2004
    Inventors: Qun Dang, Srinivas Rao Kasibhatla, K. Raja Reddy, Mark D. Erion, N. Rami Reddy, Atul Agarwal
  • Novel phosphonic acid based prodrugs of PMEA and its analogues
    Publication number: 20030229225
    Abstract: Prodrugs of Formula I, their uses, their intermediates, and their method of manufacture are described: 1
    Type: Application
    Filed: May 12, 2003
    Publication date: December 11, 2003
    Inventors: K. Raja Reddy, Mark D. Erion, Michael C. Matelich, Joseph J. Kopcho
  • Process for preparation of cyclic prodrugs of PMEA and PMPA
    Publication number: 20030225277
    Abstract: The method of preparing compounds of Formula I is described: 1
    Type: Application
    Filed: May 12, 2003
    Publication date: December 4, 2003
    Inventors: Joseph J. Kopcho, K. Raja Reddy, Michael C. Matelich, Bheemarao G. Ugarkar
  • Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase
    Patent number: 6489476
    Abstract: FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose or excess glycogen storage.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: December 3, 2002
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Qun Dang, Srinivas Rao Kasibhatla, K. Raja Reddy, Mark D. Erion, M. Rami Reddy, Atul Agarwal
  • Novel bisamidate phosphonate prodrugs
    Publication number: 20020173490
    Abstract: Novel bisamidate phosphonate prodrugs of FBPase inhibitors of the Formula IA: 1
    Type: Application
    Filed: December 22, 2000
    Publication date: November 21, 2002
    Applicant: METABASIS THERAPEUTICS, INC.
    Inventors: Tao Jiang, Srinivas Rao Kasibhatla, K. Raja Reddy
  • Benzimidazole inhibitors of fructose 1,6-bisphosphatase
    Patent number: 6399782
    Abstract: Novel benzimidazole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described
    Type: Grant
    Filed: April 11, 2000
    Date of Patent: June 4, 2002
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Srinivas Rao Kasibhatla, K. Raja Reddy, Mark D. Erion, Qun Dang, Gerard R. Scarlato, M. Rami Reddy
  • Novel prodrugs for phosphorus-containing compounds
    Publication number: 20020052345
    Abstract: Prodrugs of formula I, their uses, their intermediates, and their method of manufacture are described: 1
    Type: Application
    Filed: October 15, 2001
    Publication date: May 2, 2002
    Inventors: Mark D. Erion, K. Raja Reddy, Edward D. Robinson, Bheemarao G. Ugarkar
  • Novel aryl fructose-1,6-Bisphosphatase inhibitors
    Publication number: 20020040014
    Abstract: Novel FBPase inhibitors of the formula I 1
    Type: Application
    Filed: March 7, 2001
    Publication date: April 4, 2002
    Applicant: Metabasis Therapeutics, Inc.
    Inventors: Brett C. Bookser, Qun Dang, K. Raja Reddy
  • Prodrugs phosphorus-containing compounds
    Patent number: 6312662
    Abstract: Prodrugs of formula I, their uses, their intermediates, and their method of manufacture are described:
    Type: Grant
    Filed: September 8, 1999
    Date of Patent: November 6, 2001
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Mark D. Erion, K. Raja Reddy, Edward D. Robinson, Bheemarao G. Ugarkar
  • Indole and azaindole inhibitors of Fructose-1,6-biphosphatase
    Patent number: 6294672
    Abstract: The present invention is directed towards novel azaindole compounds which bind to the AMP site and are potent FBPase inhibitors. The present invention also is directed towards the clinical use of the novel FBPase inhibitors as a method of treatment or prevention of diseases responsive to lowered blood glucose levels.
    Type: Grant
    Filed: January 5, 2000
    Date of Patent: September 25, 2001
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: K. Raja Reddy, Gerard R. Scarlato, Qun Dang, Mark D. Erion, Srinivas Rao Kasibhatla, M. Rami Reddy
  • Purine inhibitors of fructose 1,6-bisphosphatase
    Patent number: 6284748
    Abstract: Novel purine compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described.
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: September 4, 2001
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Qun Dang, Mark D. Erion, M. Rami Reddy, Edward D. Robinson, Srinivas Rao Kasibhatla, K. Raja Reddy
  • Benzimidazole inhibitors of fructose 1,6-bisphosphatase
    Patent number: 6110903
    Abstract: Novel benzimidazole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described ##STR1##
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: August 29, 2000
    Assignee: Sankyo Company Ltd.
    Inventors: Srinivas Rao Kasibhatla, K. Raja Reddy, Mark D. Erion, Qun Dang, Gerard R. Scarlato, M. Rami Reddy
  • Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
    Patent number: 6054587
    Abstract: Novel indole and azaindole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described: ##STR1## and pharmaceutically acceptable prodrugs and salts thereof.
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: April 25, 2000
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: K. Raja Reddy, Gerard R. Scarlato, Qun Dang, Mark D. Erion, Srinivas Rao Kasibhatla, M. Rami Reddy